1. Provisional drug overdose death counts;Ahmad,2022
2. National trends in buprenorphine prescribing before and during the COVID-19 pandemic;Ali;Journal of Substance Abuse Treatment,2023
3. American Academy of Addiction Psychiatry (AAAP), American College of Academic Addiction Medicine (ACAAM), American College of Medical Toxicology(ACMT), American Osteopathic Academy of Addiction Medicine(AOAAM), American Society of Addiction Medicine (ASAM), Association for Multidisciplinary Education and Research in Substance use and Addiction (AMERSA), California Society of Addiction Medicine (CSAM), College of Psychiatric and Neurologic Pharmacists (CPNP), Massachusetts Medical Society(MMS), Massachusetts Society of Addiction Medicine (MASAM), & Oregon Society of Addiction Medicine (ORSAM). (2022). Re: A call for the FDA to retract its safety communication regarding buprenorphine. https://amersa.org/wp-content/uploads/22.01.24. A Call for the FDA to Retract its 1.12.2022 Safety Communication Regarding Buprenorphine.pdf.
4. Causal inference with observational data in addiction research;Chan;Addiction,2022
5. Improve access to care for opioid use disorder: A call to eliminate the X-Waiver requirement now;D'Onofrio;Annals of Emergency Medicine,2021